Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B-cell lymphoma.

ABSTRACT:

Background

Autoimmune conditions in B-cell lymphomas are frequent. Steroids are standard of care, but many patients require other immunosuppressive agents. Ibrutinib is a Bruton Tyrosine Kinase inhibitor that is approved for B-cell indolent lymphoma treatment. We evaluated the use of ibrutinib in previously treated hematologic immune manifestations associated with B-cell lymphomas.

Results

We conducted a retrospective multicentric observational study. Patients presenting with active, relapsed/refractory B-cell lymphoma associated hematological immune manifestation (autoimmune cytopenia, acquired immune-mediated bleeding disorders) were included. Twenty-five patients were identified. Median age at ibrutinib introduction was 69 years (range 44-84) and median number of previous

SUBMITTER: Daniel A 

PROVIDER: S-EPMC9826375 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature